2nd Next Generation Kinase Inhibitors Summit

With strong effectiveness profiles and 20 years of FDA approval, kinase inhibitors have revolutionized oncology treatment. The success of current kinase inhibitor classes is nevertheless constrained by rising resistance and security concerns.

The 2nd Next Generation Kinase Inhibitors Summit is the only industry-focused conference devoted to using novel kinase biology in drug development and innovating current programs to produce the next generation of kinase inhibitor drugs that can demonstrate effective and long-lasting clinical responses in oncology and other fields.

Now with a deeper exploration of Assay Development tools to improve experimental accuracy
AI/ML Integration into discovery and development to accelerate the development
Greater consideration of new therapeutic opportunities in novel disease areas to expand horizons

URLs:
Website: https://go.evvnt.com/1446853-0?pid=176
Brochure: https://go.evvnt.com/1446853-2?pid=176
Tickets: https://go.evvnt.com/1446853-3?pid=176

Price:
Free: USD 0.00

Speakers: Erik Schaefer, Co-Founder, President, Chief Executive Officer and Chief Scientific Officer, AssayQuant Technologies Inc., Gerhard Mueller, Chief Scientific Officer, Anavo Therapeutics, Harish Dave, Chief Medical Officer, AUM Biosciences, Terri-Anne, Cock Head of Translational Biology, Amplia Therapeutics Limited, Livio Mallucci, Professor, King's College London School of Medicine, Sandra Wiley, Director of Translational Science, MEI Pharma, Brian Ross, Professor of Biological Chemistry Director, Center for Molecular Imaging, University of Michigan, Poulikos Poulikakos, Associate Professor of Oncological Sciences, Icahn School of Medicine at Mount Sinai, Scott Foster, Principal Scientist, Genentech Inc, Matthew Robers, Senior Research Scientist and Group Leader, Promega Corporation, Federico Sesti, Professor, Rutgers University, Raghu Kalluri, Professor- Cancer Biology, University Texas MD Anderson Center, Brett King Associate, Professor of Dermatology, Yale University School of Medicine, Greg Jones, Principal Scientist, Pfizer, Adar Makovski, Silverstein Director, Corporate Development, Onconova Therapeutics, Inc., Rafael Depetris, Director of Protein Biochemistry and Structural Biology, Volastra Therapeutics, Jared Lee, Johnson Instructor, Weill Cornell - Cornell University

Time: 8:00 am to 6:00 pm